How to confirm a diagnosis by adding more markers?
Best insight from top research papers
To confirm a diagnosis by adding more markers, various methods can be employed. One approach involves utilizing a fluorescent nucleic acid nanostructure-graphene oxide complex for improved detection of multiple biomarkers through a nucleic acid pretreatment process . Another method includes the use of DNA computing and parallel rule-based classifiers based on DNA strand displacement reactions to detect multiple molecular markers efficiently . Additionally, the development of multibiomarker tests, such as protein-based tests, can aid in defining complex diseases and identifying early stages of diseases like Type 2 diabetes . Furthermore, the combination of multiple biomarkers can significantly enhance diagnostic accuracy, offering valuable insights for practitioners and clinicians . By incorporating these diverse approaches and technologies, confirming a diagnosis by adding more markers becomes a comprehensive and effective strategy in disease detection and diagnosis.
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
| Marker panels with multiple analytes can enhance diagnostic accuracy. Utilizing a multi-parameter immunochemistry platform like "IMPACT" can confirm diagnoses by combining various markers for complex disease detection. | |
| Utilizing microfluidics for multibiomarker tests can confirm diagnoses by analyzing multiple markers simultaneously, enhancing diagnostic accuracy and enabling early disease detection. | |
| By utilizing a fluorescent nucleic acid nanostructure-graphene oxide complex and a nucleic acid pretreatment process, multiple biomarkers can be detected selectively, improving diagnosis accuracy even at low concentrations. | |
01 Oct 2016 1 Citations | By utilizing a parallel rule-based classifier with DNA strand displacement, multiple molecular markers can be detected simultaneously, aiding in confirming a diagnosis by adding more markers efficiently. |
3 Citations | Combining multiple functional markers enhances diagnostic accuracy, aiding in confirming diagnoses by leveraging a variety of biomarkers, as highlighted in the research. |
Related Questions
What is marker completeness?5 answersMarker completeness refers to the extent to which a specific marker or trait is accurately tested and reported in a given study or dataset. In the context of brain tumors, the completeness of brain molecular marker (BMM) testing and reporting was evaluated, showing variations based on hospital attributes and the extent of resection. For instance, in the study of adult-type diffuse gliomas, the overall completeness of BMM testing was found to be 81%, with higher rates associated with more extensive resections and certain types of medical facilities. This assessment of marker completeness is crucial for ensuring the reliability and accuracy of research findings and clinical decisions related to the specific marker being studied.
What are the current predictive markers being used to diagnose neuropathy in colorectal patients?5 answersCurrent predictive markers for diagnosing neuropathy in colorectal cancer patients include circulating long non-coding RNA (lncRNA) levels in plasma extracellular vesicles, microsatellite instability (MSI) phenotype, inflammatory markers including blood cell ratios, cell-free DNA (cfDNA), circulating tumor cells (CTC), and microRNAs (miRNAs), and genetic markers identified through genome-wide association analysis. These markers can help predict the occurrence and development of neuropathy, as well as the response to specific treatments. The use of lncRNA levels in plasma extracellular vesicles may be particularly effective in predicting long-lasting peripheral neuropathy and guiding the continuation of oxaliplatin treatment. Additionally, the identification of genetic polymorphisms in specific genes such as TAC1, FOXC1, ITGA1, ACYP2, DLEU7, BTG4, CAMK2N1, and FARS2 can provide personalized chemotherapy options for patients with severe oxaliplatin-induced chronic peripheral neuropathy.
Can sfts peptide markers be used as potential biomarkers for early detection and diagnosis of specific medical conditions?5 answersSFTS peptide markers have the potential to be used as biomarkers for early detection and diagnosis of specific medical conditions. Proteomic analysis of SFTS patient samples revealed that the nucleocapsid (N) protein is a major antigen protein in sera of SFTS patients, and the N-terminal tryptic peptide of the N protein could be a useful proteomic target for direct detection of SFTS virus. In silico technology was used to generate specific data for parental antimicrobial peptides (AMPs) that can identify viral and bacterial pneumonia pathogens. These AMPs have the potential capacity to detect pneumonia caused by these pathogens with high sensitivity, accuracy, and specificity, making them suitable for point-of-care diagnosis. A protein containing a peptide fragment has been developed for diagnosing the prognosis condition of an SFTS patient. This protein can detect the presence of a protective antibody in the patient's body and judge the patient's prognosis condition, with positive detection indicating a good prognosis and negative detection indicating a poor prognosis. Peptides have been identified as promising biomarkers due to their small size, stability, easy production, and ability to mirror changes in protease expression associated with pathological processes.
How can the x-tile algorithm be used to find the cut-point for a diagnostic marker?5 answersThe X-tile algorithm is used to find the cut-point for a diagnostic marker by visualizing the relationship between biomarker expression and outcome. It constructs a two-dimensional projection of every possible subpopulation, allowing for the identification of substantial tumor subpopulations and the robustness of the biomarker-outcome relationship. The X-tile plot has been validated in breast cancer patients, where it accurately predicts population subsets based on the expression of established prognostic markers. In the context of hepatocellular carcinoma (HCC), the X-tile software was used to optimize the cut-point for glypican-3 (GPC3) expression, which was found to be significantly correlated with overall survival and time to recurrence. In the field of posttraumatic stress disorder (PTSD), the X-tile algorithm was compared to a symptom-based algorithm for scoring the PTSD Checklist (PCL), and a cut-point of 42 was found to distinguish optimally between PTSD and non-PTSD groups.
What are the new markers in clinical diabetes?5 answersNovel biomarkers have emerged in the field of clinical diabetes for early detection and risk stratification. These biomarkers include glucated hemoglobin, glucated albumin, fructosamine, 1,5-anhydroglucitol, lipid hydroperoxides (LOOH), malondialdehyde (MDA), thiobarbituric reactive substances (TBARS), neutrophil-lymphocyte ratio (NLR), and platelet lymphocyte ratio (PLR). These markers have shown potential in assessing risk stratification, identifying oxidative stress, and predicting future complications associated with diabetes. Additionally, microRNAs released by stressed pancreatic islets during prediabetes have been studied as potential markers for different modes of diabetes. These markers have the potential to aid in early detection, classification, and treatment of diabetic conditions, ultimately preventing and reversing diabetes. However, it is important to note that the practical use of these biomarkers may be limited by their specificity and cost-effectiveness.
What are the latest markers for type 2 diabetes?5 answersSeveral novel biomarkers have emerged in recent years for the detection and prediction of type 2 diabetes (T2DM). These biomarkers include microRNAs (miRNAs) found in various body fluids, such as blood, that have shown significant concentration differences between individuals who progress from prediabetes to T2DM and those who remain prediabetic. Additionally, a comprehensive bioinformatics analysis of microarray data has identified candidate genes that are directly or indirectly linked to T2DM, including those involved in inflammatory response, lipid metabolic process, and cell death regulation. Furthermore, the random amplified polymorphism DNA (RAPD) method has been used to identify genetic markers associated with T2DM, with a specific 576 bp band confirmed as a marker in T2DM patients. These novel biomarkers and genetic markers hold promise for improving the early detection and risk prediction of T2DM.